Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses ongoing randomized studies of Selinexor and Selinexor with chemotherapy, single-agent…
John M Burke, MD from Rocky Mountain Cancer Centers discusses CAR-T cell therapy with diffuse Large-B-cell Lymphoma and more CAR-T…
Stephen Hunger, MD from Children’s Hospital of Philadelphia discusses further immunotherapy research in 2018-19 and the incorporation of new drugs…
John M Burke, MD from Rocky Mountain Cancer Centers discusses lymphoid malignancies treatment developments and replacement of Bleomycin with Brentuximab…
Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses developments of Phase 3 trial: BOSTON – Bortezomib in combination…
Stephen Hunger, MD from Children’s Hospital of Philadelphia discusses patients with Philadelphia Chromosome+ ALL can be cured and limited use…
John M Burke, MD from Rocky Mountain Cancer Centers discusses new Phase 3 Murano trial for CLL and Venetoclax &…
Ruben Mesa, MD from UT Health San Antonio Cancer Center discusses individualized medicine in 2018 and therapies based on tumor…
John M Burke, MD from Rocky Mountain Cancer Centers discusses monitor patients minimal residual disease status and maintenance doses of…
Stephen Hunger, MD from Children’s Hospital of Philadelphia discusses successor trials from North American and European group and testing imatnib…
Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses Selinexor its mechanism of action and as it restores the…
Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses a new oral compound, Selinexor and how it can be…
John M Burke, MD from Rocky Mountain Cancer Centers discusses a new study with diffuse large B-cell lymphoma and improvements…
Ruben Mesa, MD from UT Health San Antonio Cancer Center discusses subgroups of patients who benefit from interferon and delaying…
Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses high-response rates from both Selinexor and velcade and the combination…
Stephen Hunger, MD from Children’s Hospital of Philadelphia discusses Phase 2 trial of dasatinib with Philadelphia Chromosome+ ALL and the…
John M. Burke, MD from Rocky Mountain Cancer Centers discusses use of rituximab after bendamustine is relatively safe at the…
Ruben Mesa, MD from UT Health San Antonio Cancer Center discusses impact of immune-based therapies and great impact on lymphoid…
Michael Kauffman, MD from Karyopharm Therapeutics Inc discusses additional combinations with Selinexor & pomalidomide, revlimid, daratumumab at the 2017 American…
Stephen Hunger, MD from Children’s Hospital of Philadelphia discusses EsPhALL regimen and adding Dasatnib to intensive chemotherapy backbone at the…
John M. Burke, MD from Rocky Mountain Cancer Centers discusses multiple myeloma study and added daratumumab towards CD38 at the…
Dr. Jack West reviews the results and pending questions of the KEYNOTE-189 trial of chemotherapy with or without pembrolizumab (KEYTRUDA)…
Soulen – Who Should Get PRRT Weighing Cumulative Toxicity Key to PRRT Treatment Michael C. Soulen, MD of the University…
Michael C. Soulen, MD of the University of Pennsylvania discusses primary resection of tumor in the gut and how there…
Michael C. Soulen, MD of the University of Pennsylvania discusses that peptide receptor radionuclide therapy US approval expected early 2018…
Michael C. Soulen, MD of the University of Pennsylvania answers the question “Is PRRT Practice Changing?”. He summarizes that cost,…
Identifying the optimal means of introducing biosimilars is an issue facing all clinics. Biosimilar rituximab was introduced in Oxford, UK…
Biosimilar licensing represents a huge opportunity for the NHS to make vital cost savings. In this interview, recorded at the…
In this interview, Ms Man-Chie Chow from the Royal Surrey County Hospital, Guildford, UK gives a brief overview of the…
The method of how new medication is determined to be cost-effective serves a crucial role in drug access. Here, Ms…
Affordable treatment reduces the burden on the healthcare services and increases the chances of NICE approval. Speaking from the British…
Streamlining the administration process of drug price agreements can greatly reduce the labor of pharmacists. In this interview at the…
Damian J. Green, MD, from Seattle Cancer Care Alliance discusses Identifying Minimum Residual Disease using Flow Cytometry and Next Gen…
Damian J. Green, MD, from Seattle Cancer Care Alliance discusses the Role of Tandem Autologous Transplant and PFS and Overall…
Damian J. Green, MD, from Seattle Cancer Care Alliance discusses Radiolabeled CD45 in Stem Cell Transplant For High Risk Multiple…
Damian J. Green, MD, from Seattle Cancer Care Alliance discusses a New Trial CAR T-Cells Targeting BCMA For Multiple Myeloma…
Damian J. Green, MD, from Seattle Cancer Care Alliance discusses how Allogeneic Stem Cell Transplant with Busulfan may Possibly improve…
There are now three small molecule inhibitors to choose from for the treatment of chronic lymphocytic leukemia (CLL): Ibrutinib, idelalisib…
With many promising novel therapeutic agents exiting pharmaceutical pipelines, a question that arises is whether standard chemotherapy regimens with long-term…
A novel BTK inhibitor, acalabrutinib, is showing promise in the early clinical trial stages for chronic lymphocytic leukemia (CLL). Speaking…
Antibody-chemotherapy combinations are a standard treatment for hematological malignancies, and with an increase in small molecules coming through the pharmaceutical…
Older patients with acute lymphoblastic leukemia (ALL) have significantly worse outcomes; thus, there is a great need for improved treatments…
In this interview, Susan OBrien, MD, of the University of California, Irvine, CA, talks to us about the next-generation PI3K?…
One of the controversies surrounding the use of minimal residual disease (MRD) is the optimal technique for its assessment. Speaking…
The use of minimal residual disease (MRD) status in the clinic and trials is a promising, yet controversial, area of…
The treatments available for smoldering multiple myeloma (MM) are limited, with typical recommendations of observation or enrollment in clinical trials.…
Next-generation sequencing (NGS) has been widely used in research for the past decade or more; however, its translation into the…
When FLT3 inhibitors were first on the horizon, expectations were high, with hopes that they would have a similar level…
The development of IDH inhibitors for acute myeloid leukemia (AML) has been a smoother journey than that for FLT3 inhibitors.…
Researchers and clinicians now recognize that AML comprises a multitude of subtypes. In this interview, Richard Stone, MD, of the…
In this interview, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, gives his forecast of the acute myeloid…
In this interview, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, provides an overview of the Phase III…
Robert Z. Orlowski, MD, from MD Anderson Cancer Center discusses Phase III Trial for multiple myeloma and Busulfan + Melphalan…
Sattva S. Neelapu, MD from MD Anderson Cancer Center discusses ZUMA-1 trial long term follow up and very few long…
Robert Z. Orlowski, MD, from MD Anderson Cancer Center discusses the phase II study in multiple myeloma and the combination…
Ruben Mesa, MD, from UT Health San Antonio Cancer Center discusses risks of toxicity with interferon and chronic low-grade toxicities…
Sattva S. Neelapu, MD from MD Anderson Cancer Center discusses mechanics of CAR-T cell therapy and combining axi-cel with an…
Gareth Morgan, MD, from University of Arkansas for Medical Sciences discusses immunoactive treatments and bispecific antibodies, CAR-T cells, and monovalent…
Robert Z. Orlowski, MD, PhD, from MD Anderson Cancer Center discusses myeloma drugs for 2018 and anti-body drug conjugates, Bi-specific…
Joseph M. Connors, MD from British Colombia Cancer Agency discusses the new chemotherapy combination works better than previous and information…
Sattva S. Neelapu, MD from MD Anderson Cancer Center discusses FDA’s approval of Axi-Cel and 42% of patients have long-term…
Ruben Mesa, MD from UT Health San Antonio Cancer Center discusses Pegylated Interferon Alfa-2a and the utilization of Interferon on…
Habte Yimer, MD from Texas Oncology discusses safety for the 1st cycle of CyBorD and how it decreases infusion time…
Aziz Nazha, MD from Cleveland Clinic discusses the importance of prognosis on oncology and the probability of outcome of disease…
Robert Z. Orlowski, MD from MD Anderson Cancer Center discusses Ixazomib for maintenance in multiple myeloma and Ixazomib maybe approved…
Gareth Morgan, MD from University of Arkansas for Medical Sciences discusses double-hit myeloma and bialellic activation of P-53, ISS stage…
Dr. Peter Lucas, Director of Laboratory Services & Principal Investigator at NSABP, discusses clinical trial testing.
Habte Yimer, MD from Texas Oncology discusses Phase 2 study of Daratumumab and assess good, partial, or better response after…
Joseph M. Connors, MD from British Colombia Cancer Agency discusses developments with immunotherapy and lymphoid malignancies – Checkpoint inhibitors and…
John M. Burke, MD from Rocky Mountain Cancer Centers discusses Rituximab after Bendamustine – Rituximab maintenance improved PFS at the…
Sattva S. Neelapu, MD from MD Anderson Cancer Center discusses CAR-T cell therapy in large cell Lymphoma – 80 response…
Robert Z. Orlowski, MD from MD Anderson Cancer Center discusses if MRD negative patients can stop maintenance and continue treatment…
Habte Yimer, MD from Texas Oncology discusses Daratumumab studies have shown significant benefits and effective in combination with CyBorD at…
Gareth Morgan, MD from University of Arkansas for Medical Sciences discusses developing data will help clinicians and CAR-T cells are…
Ruben Mesa, MD from UT Health San Antonio Cancer Center discusses MPD-RC 111 protocol for patients with polycythemia vera or…
Personal digital disease tracking enables patients and the multidisciplinary team managing their care to better monitor their disease. Speaking from…
Digital technologies can aid both patients and clinicians in managing a disease. Here, Nina Paton from The Christie NHS Foundation…
There is a lack of funding for research into certain cancer types, such as lung and pancreatic cancer, compared with…
Speaking from the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Islam Elkonaissi of The Royal…
Exciting clinical updates for lung and pancreatic cancer were presented at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium…
In this presentation from the ‘Looking Closely at New Therapeutic Options for Hepatocellular Carcinoma’, Dr. Bruno Daniele discusses the latest…
In this presentation from the ‘Looking Closely at New Therapeutic Options for Hepatocellular Carcinoma’, Dr. Jordi Bruix discusses novel treatment…
In this presentation from the ‘Looking Closely at New Therapeutic Options for Hepatocellular Carcinoma’, Dr. Luigi Bolondi discusses the latest…
Joseph M. Connors, MD from British Colombia Cancer Agency discusses the progress that has been made combatting Hodgkins lymphoma and…
Robert Z. Orlowski, MD from MD Anderson Cancer Center discusses further research in Multiple Myeloma and adapting to a minimal…
John M. Burke, MD from Rocky Mountain Cancer Centers discusses new conjugate CD 79 and relapsed refractory B-Cell at the…
Aziz Nazha, MD from the Cleveland Clinic discusses predicting Survival Myelodysplastic Syndrome and using the Random Survival Forest Algorithm at…
Alok Khorana, MD from the Cleveland Clinic discusses studies in 2018 and CASSINI and Apixaban for the prevention of VTE…
Sattva S. Neelapu MD, from MD Anderson Cancer Center discusses beyond ZUMA-1 and evaluating Axi-Cel efficacy at the 2017 American…
Robert Z. Orlowski, MD, PhD, from The University of Texas MD Anderson Cancer Center discusses multiple myeloma studies for 2018…
The production of novel anti-cancer treatments has taken cancer therapy to a point that was previously unimaginable. Here, Jeff Evans,…
Joseph M. Connors, MD from British Colombia Cancer Agency discusses results of the Echelon-1 Trial and new chemotherapy that is…
When helping patients through their treatment, CRUK and Macmillan Cancer Support act as fantastic allies for pharmacists. In this interview,…
Jackie Lewis, BPharm, MRPharmS, PhD of Lewis Pharmacy, Devon, UK discusses the evolution of cancer care in community pharmacies. Dr…
As the demand on healthcare services increases, novel and innovative ways to meet that demand need to be created. In…
Speaking from the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Jackie Lewis, BPharm, MRPharmS, PhD…
Aziz Nazha, MD from the Cleveland Clinic discusses algorithm picks relevant variables and variables help predict survivability with myelodysplastic syndromes…
There are now many drugs available for the treatment of chronic lymphocytic leukemia (CLL); however, there is only limited data…
The optimal treatment for younger patients with relapsed/refractory chronic lymphocytic leukemia (CLL) depends on a number of factors, including what…
There are now many effective therapies to choose from for chronic lymphocytic leukemia (CLL). Thus, a recent area of therapeutic…
Richters transformation remains a challenge in chronic lymphocytic leukemia (CLL). In this interview, Matthew Davids, MD, of the Dana-Farber Cancer…
John M. Burke, MD from Rocky Mountain Cancer Centers discusses Atezolizumab + Bendamustine & Obinutuzumab and no major safety signals…
Targeted therapies have revolutionized the treatment of cancer; however, under the selective pressures exerted by these therapies, tumor cells with…
TAK-659 is a novel FLT3 inhibitor in the initial trial stages for the treatment of acute myeloid leukemia (AML). Interestingly,…
Although our knowledge of the underlying genetic causes of acute myeloid leukemia (AML) and their consequent molecular results has progressed…
In patients whose cancer is primarily caused by a specific mutation, tests which enable the determination of variant allele frequency…
Robert Z. Orlowski, MD, PhD, from The University of Texas MD Anderson Cancer Center discusses combinations well tolerated in multiple…
Sattva S. Neelapu, MD, from the University of Texas MD Anderson Cancer Center discusses how Axi-Cel is a milestone for…
Alok Khorana, MD of the Cleveland Clinic discusses the prevalence and consequences of VTE and increased chance of fatality and…
Joseph M. Connors, MD, FRCPC from The BC Cancer Agency Research Centre discusses checkpoint inhibitors in Hodgkin’s lymphoma and immune…
Although great strides have been made in cancer treatment and diagnosis, in many types of cancer these aspects are still…
There is a constant need for new knowledge discovery in cancer biology; we do not yet fully understand the underlying…
Modern machinery learning techniques allow for the processing of large quantities of cancer images, at a much faster rate than…
Artificial neural networks that can process information have existed for a long time. However, in recent years greater computing power…
Although there are few data sets available to researchers in cancer imaging compared with other fields, experts are able to…
When studying patient data, many fields of cancer medicine will have large databases containing information from tens of thousands of…
The immunoscore is a predictive tool that looks at a cancer patients adaptive immunity to predict survival and recurrence, amongst…
An immunoscore is an evaluative test of a cancer patients adaptive immune activity towards their tumor, and can predict survival,…
The immunoscore is a predictive tool that scores cancer patients based on an evaluation of their adaptive immunity. In this…
It is important that we have accurate models for the risk stratification of cancer patients, in order to determine how…
There are many ways of predicting cancer recurrence and survival; these include pathology-based tests, such as tumor grade, molecular markers,…
In recent years, the interest of the scientific community in the immune system as it relates to cancer has greatly…
Knowledge is evolving regarding numerous clinical aspects of immune thrombocytopenia purpura (ITP), and there remains significant variability in clinical practice…
In this Key Insights activity, Drs. Corey J. Langer, MD and Joshua Bauml discuss the key take-home points from the…
Recent developments in research allowing for the DNA analysis of formalin-fixed samples have allowed for greater accessibility to tumor sample…
Proton beam therapy is a high energy, localized form of radiation therapy that has the potential to greatly improve the…
Recent research has demonstrated that a lot of information about a cancer can be elucidated from a formalin-fixed sample, as…
With the NHS opening two high energy proton beam centers next year, optimism is high in the medical community for…
Even though the UKs first high energy proton beam centers are yet to open, it is critical to look forward…
The NHS is opening its first two high energy proton beam therapy centers in 2018 and 2020, at great financial…
The dissemination and sharing of scientific knowledge is key to improving healthcare practices on a national and international scale. In…
Novel immunotherapies have great potential to improve the survival of cancer patients; however, new treatments must be introduced in a…
The early diagnosis of cancer is key to survival; however, with the many demands upon the NHS this can be…
CRUK is well known for scientific research; however, it also employs other channels to transition the results of this research…
The CRUK Facilitator programme is collaborating with community pharmacists to provide training and resources. In this interview, Gillian Phillips from…
The earlier cancer is diagnosed, the higher the chance of recovery. At the British Oncology Pharmacy Association (BOPA) 20th Annual…
Immunotherapy for acute myeloid leukemia (AML) is an exciting area, with clinical trials, including those that are first-in-human, showing promising…
There were impressive updates on venetoclax combination studies for elderly acute myeloid leukemia (AML) that are progressing at the American…
E-selectin is involved in the progression of acute myeloid leukemia (AML), playing a key role in angiogenesis, thus making it…
In this exciting interview from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Maria-Victoria…
SYK, which directly binds to and activates FLT3, has been implicated in the pathogenesis of B-cell malignancies, making it a…
There have been great advances in the targeting of FLT3 for acute myeloid leukemia (AML) in recent years, many of…
FLT3 ITD acute myeloid leukemia (AML) is associated with high rates of relapse, after which prognosis is very poor. Thus,…
There are now several novel drugs targeting the protein kinase FLT3 in patients with acute myeloid leukemia (AML). Here, Keith…
Recent data have suggested that chronic lymphocytic leukemia (CLL) patients, in particular those with mutated immunoglobulin heavy chain genes, can…
Ibrutinib is associated with a range of side effects, including increased bruising, TKI ecchymosis, low-grade bleeding and hemorrhage. This has…
A range of chronic lymphocytic leukemia (CLL) research was presented at the American Society of Hematology (ASH) 2017 Annual Meeting…
Despite the combination of ibrutinib and rituximab not significantly affecting progression-free survival in patients with chronic lymphocytic leukemia (CLL), many…
The targeted agent ibrutinib has been tested as a first-line monotherapy in elderly chronic lymphocytic leukemia (CLL) in the RESONATE-2…
Decitabine, a DNA methyltransferase (DNMT) inhibitor, which is given to patients with myelodysplastic syndromes (MDS), is classically administered intravenously. Now,…
Clinical access to new technologies, such as next-generation sequencing (NGS), can revolutionize the treatment of cancer. In this interview, Guillermo…
Pracinostat is a histone deacetylase (HDAC) inhibitor that has demonstrated very promising efficacy in acute myeloid leukemia (AML) and myelodysplastic…
In cutaneous T-cell lymphoma (CTCL) miR-155 has been shown to be upregulated. Here, Christiane Querfeld, MD, PhD, of City of…
Immune checkpoint inhibitors have now entered the treatment landscape for cutaneous T-cell lymphoma (CTCL). In this interview, Christiane Querfeld, MD,…
CAR T-cell therapies have exhibited strong and durable responses in several hematological malignancies thus far. Now bb2121, an anti-BCMA CAR…
For CAR T-cell therapy to become mainstream, the management of related toxicities needs to be addressed. Speaking from the American…
Immunotherapy for lymphoid malignancies progressed dramatically in 2017, with FDA approval of two CAR T-cell products, axicabtagene ciloleucel and tisagenlecleucel.…
The Phase I/II trial ZUMA-1 (NCT02348216) was pivotal for CAR T-cell development. In this interview, Yi Lin, MD, PhD, of…
The ground-breaking PRECISION-Panc project aims to speed up scientific discovery to improve the survival rates of patients with pancreatic cancer.…
The imminent pancreatic cancer trial PRIMUS001 (ISRCTN75002153) has the potential to personalize therapy for patients with pancreatic cancer. In this…
This is an exciting time for pancreatic cancer research, with advances in immunotherapy, genomic sequencing and druggable targets. What the…
There is a necessity for further clinical trials and research into pancreatic cancer in order to improve patient outcomes. In…
Although progress has been made in the treatment of pancreatic cancer, further research is required to identify novel therapeutic options…
How can patients navigate between treatment options with all of the recent breakthroughs in myeloma therapy? Dr. Guilherme Perini, a…
Where is lymphoma treatment today? Stay in the know with Brazilian hematologist Dr. Guilherme Perini as he discusses advances in…
The landscape of myeloma care is constantly evolving with the development of new research and treatment. While advances in myeloma…
What have researchers discovered about ROR1 and its role in targeted CLL therapies? Andrew Schorr hosts coverage from the 2017…
Can todays medicines be used together to treat CLL more effectively? CLL expert Dr. Michael Choi of UC San Diego…
Where do things stand now with personalizing myeloma therapy to a patients genetic profile? At the American Society of Hematology…
The first relatively long-term CAR T-cell trial follow-up data came out at the American Society of Hematology (ASH) 2017 Annual…
The right balance of T-cell expansion needs to be achieved in order to obtain the optimal response to CAR T-cell…
Cytokine release syndrome (CRS) is a relatively well-described toxicity of CAR T-cell therapy. However, their may be delayed manifestations of…
With CAR T-cell therapy, similarly to traditional chemotherapy, the use of a single agent will not remain effective in treating…
CAR T-cell therapy development is progressing across a wide range of hematological malignancies, with the results highly anticipated in acute…
An exciting new CAR T-cell product, which targets SLAMF7 (CS1, CD319), is displaying exciting preliminary results against multiple myeloma (MM)…
A major concern surrounding novel therapeutics is their safety, which must be characterized thoroughly. Here, Sattva Neelapu, MD, from the…
The latest CAR T-cell data was highly anticipated at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition…
Chimeric antigen receptor (CAR) T-cell therapy has been receiving buzz as a promising treatment for cancer patients. So which CAR…
Whats the latest information about MPN treatment and research? As part of our ASH 2017 coverage, Dr. John Crispino and…
What does the future of treatment for mantle cell lymphoma look like? From the 2017 American Society of Hematology (ASH)…
Whats the latest news on CAR-T cell therapy from the American Society Hematology (ASH) conference 2017 as we report on…
As part of our coverage of the 2017 American Society of Hematology (ASH) meeting in Atlanta, Dr. Srdan Verstovsek, an…
Will flow be the method used for myeloma treatment in the long term? Does transplant still have a role in…
Whats the latest in mantle cell lymphoma research? Esther Schorr, on location at the 2017 American Society of Hematology (ASH)…
As part of our coverage from the 2017 American Society of Hematology (ASH) annual meeting, A super panel of MPN…
Patient Power founders Andrew and Esther Schorr are joined by MPN expert Dr. Naveen Pemmaraju of MD Anderson Cancer Center,…
Roy S. Herbst, MD, PhD of Yale Cancer Center talks about EGFR inhibitor resistant patients and how EGFR antibodies may…
Roy S. Herbst, MD, PhD of Yale Cancer Center discusses EGFR small molecules versus antibodies in combination antibodies better than…
Jun J. Mao, MD of Memorial Sloan Kettering Cancer Center explains why oncologic supplements and diet correlative evidence is incomplete…
Roy S. Herbst, MD, PhD of Yale Cancer Center discusses how the FLAURA data & Osimertinib result in high PFS…
Jun J. Mao, MD of Memorial Sloan Kettering Cancer Center discusses how physical activity and fitness help lung cancer patients…
Jim L. Mulshine, MD of Rush University talks about the 2015 lung cancer screening data from the American Cancer Society,…
Jennifer S. Temel, MD of Mass General Hospital – Harvard Medical School explains how engaging patients talk about end of…
Roy S. Herbst, MD, PhD of Yale Cancer Center discusses lung cancer EGFR antibodies and where the research is going.…
Jun J. Mao, MD of Memorial Sloan Kettering Cancer Center discusses the definition of integrative oncology which they published a…
Jim L. Mulshine, MD of Rush University talks about computed tomography which can be used not just for lung cancer…
Daniel A. Pryma, MD of the University of Pennsylvania highlights one common question – when should a patient have his…
Jennifer S. Temel, MD of Mass General Hospital – Harvard Medical School discusses how involving palliative care earlier in the…
Roy S. Herbst, MD, PhD of Yale Cancer Center talks about possible flurry of activity that focuses on resistance to…
Jun J. Mao, MD of Memorial Sloan Kettering Cancer Center discusses how integrative medicine can improve health, quality of life,…
Jim L. Mulshine, MD of Rush University discusses costs of new lung cancer services and the aging population burdening current…
Paul K. Paik, MD of Memorial Sloan Kettering Cancer Center discusses Cobas EGFR mutation test v2 and the ability to…
Jennifer S. Temel, MD of Mass General Hospital – Harvard Medical School discusses how most patients prefer to die at…
Roy S. Herbst, MD, PhD of Yale Cancer Center discusses screening for EGFR mutation and why all lung cancers should…
Jun J. Mao, MD of Memorial Sloan Kettering Cancer Center discusses integrative oncology and how complementary therapy may be beneficial.…
Jim L. Mulshine, MD of Rush University explains that the national lung screening trial had a more diverse population than…
Paul K. Paik, MD of Memorial Sloan Kettering Cancer Center discusses the PFS of FLAURA trial compared to first generation…
Daniel A. Pryma, MD of the University of Pennsylvania discusses how fluorodeoxyglucose (FDG) PET scan is still powerful tool for…
Jennifer S. Temel, MD of Mass General Hospital – Harvard Medical School discusses patient prognosis perception and how it impacts…
Roy S. Herbst, MD, PhD of Yale Cancer Center discusses squamous cell carcinoma 4+ EGFR and giving carboplatin cetuximab safely…
Jun J. Mao, MD of Memorial Sloan Kettering Cancer Center discusses a study where yoga may benefit cancer patients in…
Jim L. Mulshine, MD of Rush University discusses the veterans administration’s lung cancer pilot study that about 40% of scans…
Paul K. Paik, MD of Memorial Sloan Kettering Cancer Center discusses that there is short-term and long-term hope for squamous…
Daniel A. Pryma, MD of the University of Pennsylvania discusses the challenges of imaging immunotherapy for lung cancer. In the…
Jennifer S. Temel, MD of Mass General Hospital – Harvard Medical School discusses how prognosis, treatment goals and how end…
The stimulating area of CAR T-cell therapy is currently limited due to a range of factors, which must be overcome…
The efficacy results of the major CAR T-cells in development have been very positive. In this interview, Jeremy Abramson, MD,…
The assistance obtained from outside of GP clinics and hospitals is essential in the treatment of cancer patients. In this…
Supportive care is an essential element of the overall management of patients with cancer. Speaking from the British Oncology Pharmacy…
Carl Booth, MPhil BPharm MRPharmS, of Airedale NHS Foundation Trust, Keighley, UK provides an overview of the abstract selection process…
Carl Booth, MPhil BPharm MRPharmS, of Airedale NHS Foundation Trust, Keighley, UK talks to us about the key topics presented…
Carl Booth, MPhil BPharm MRPharmS, of Airedale NHS Foundation Trust, Keighley, UK, talks to us about collaboration amongst pharmacists to…
In this Ask the Expert segment, a Patient Power community member wants to know Are there recommendations for vaccines for…
During this Ask the Expert segment, a community member with essential thrombocythemia (ET) wants to know about increased risk for…
Dr. Abdulraheem Yacoub explains how CAR-T cell therapy targets cancer cells in the body and what the future holds for…
The ways in which healthcare providers function must change to keep up with increasing demand. In this video, Bryn Thomas…
Communicating and learning from shared experiences aids in the improvement of medical practices. In this interview, Bryn Thomas of The…
In todays digitally advanced society, large volumes of patient-level data can be collected and compiled. With an ever-increasing demand upon…
How is the role of the pharmacist changing as treatments in hematological cancers develop? Susannah Koontz Webb, PharmD, BCOP, FHOP,…
Susannah Koontz Webb, PharmD, BCOP, FHOP, President of the Hematology Oncology Pharmacy Association (HOPA) discusses her session on Collaborative Projects…
During the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, we met with Susannah Koontz Webb,…
An important question regarding the use of biosimilar rituximab is whether rapid infusion rates are safe, as they are for…
David Irvine from the Beatson Institute, Glasgow, UK discusses introducing CAR-T cells and other cellular therapies into clinical practice and…
Several major breakthroughs in the treatment of amyloid light-chain (AL) amyloidosis were presented at the American Society of Hematology (ASH)…
This is an exciting time in hemeonc, with new treatment paradigms across a range of malignant hematologies, including multiple myeloma…
The use of frontline autologous stem cell transplantation (ASCT) for newly diagnosed multiple myeloma (MM) has been questioned due to…
The proteasome inhibitor carfilzomib has been investigated for the treatment of relapsed/refractory multiple myeloma (MM) in two Phase III clinical…
The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA presented exciting results from the ASPIRE…
The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, presented exciting data on the use…
Treating cancer beyond progression is an important option to be considered in cases where the benefits outweigh the risks. Speaking…
An update on the results of the Phase III ECHELON-1 study (NCT01712490), comparing ABVD vs. AVD plus brentuximab vedotin in…
CAR T-cells are a particularly exciting therapeutic area, which was widely covered at the American Society of Hematology (ASH) 2017…
Following on from the success of brentuximab vedotin, new antibody-drug conjugates (ADCs) for lymphoma are on the horizon. These successors…
Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in PV Patients. Two – year results from the…
Anne S. Tsao, MD of MD Anderson Cancer Center discusses two reasons Osimertinib is good for first line treatment such…
Anne S. Tsao, MD of MD Anderson Cancer Center discusses third generation TKIs and how they cause less diarrhea, abdominal…
Anne S. Tsao, MD of MD Anderson Cancer Center discusses profiling standards for NSCLC blood & tissue especially for oncogenic…